Clinical Trials

Searchable database of currently enrolling clinical trials
From the Editor

Non-metastatic castration-resistant prostate cancer, a disease state misnomer that is a seriously unmet therapeutic need

Evan Y. Yu
March 14, 2017

Non-metastatic (M0) castration-resistant prostate cancer (CRPC) is truly a misnomer.  It is meant to highlight a prostate cancer disease state that solely exists because of the use of prostate-specific antigen (PSA).  In most fields, patients either have localized disease or radiographically-detectable metastatic disease.  Since PSA is a highly sensitive measure of detection, our field is able to detect microscopic metastases due to limits of standard imaging modalities. 


Dr. Evan Yu, MD

Evan Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Professor, Department of Medical Oncology, University of Washington School of Medicine
  • Member, Fred Hutchinson Cancer Research Center
  • Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.